Vitiligo is a chronic skin depigmentation disorder characterized by the destruction of melanocytes. The etiology is multifactorial; both genetic and environmental factors are implicated in disease initiation. The burden on patients is high owing to the disease’s social stigma, which negatively impacts patients’ QOL. Although no therapies are approved for vitiligo, treatment providers commonly prescribe topical/oral steroids or other immunomodulators alone or in combination with narrow-band UVB. The vitiligo pipeline is dominated by investigational JAK inhibitors that are being developed in oral or topical formulations. If proven efficacious, these agents will enjoy huge commercial opportunities because of the immense unmet need in this space.
United States Primary Research
3 KOL interviews in January 2020
KEY COMPANIES COVERED
Incyte, Pfizer, Dermavant, Clinuvel
KEY DRUGS COVERED
Ruxolitinib, Cerdulatinib, PF-06651600, PF-06700841, Afamelanotide
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, bio-therapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.